Memory Impairment Clinical Trial
— BRAINBOOSTEROfficial title:
Evaluation of the Effect of Peptides and n-3 Polyunsaturated Fatty Acids (n-3 PUFAs) From a Blue Fish Hydrolysate on Memory in Healthy Elderly People : a Randomised, Placebo-controlled, Double-blind Study.
Verified date | January 2024 |
Source | Abyss Ingredients |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This interventional, randomised, placebo-controlled and double-blind study aims to evaluate the effect of a dietary supplementation with a blue fish hydrolysate derived from marine by-products, containing peptides and n-3 polyunsaturated fatty acids, on cognitive performance in a healthy older population, between 60 and 73 years old, with lower memory performance.
Status | Completed |
Enrollment | 53 |
Est. completion date | August 10, 2023 |
Est. primary completion date | August 10, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years to 73 Years |
Eligibility | Inclusion Criteria: - Male or female subjects, aged between 60 and 73 years old (including age limits), - BMI between 20 and 30 kg/m2, - Not diagnosed with Alzheimer's disease and autonomous, - 26 < MMSE <= 29, - PAL TEA > 57, - Affiliated with a social security plan, - Able to understand the study and consent, - Available to come to the 5 visits required for the study, - Informed and have signed an informed consent. Exclusion Criteria: - Person who has participated in the last 3 months or is currently participating in another clinical trial that may interfere with the evaluation of the primary endpoint (memory). - Subject consuming food supplements likely to have an effect on memory or within less than 6 months - Subject consuming high level of Vitamin A and/or Long chain n-3 PUFA evaluated by a food frequency questionnaire - Restrictive or unbalanced diet (hypocaloric, vegetarian, vegan, …) self-declared at V0 - Fish consumption more than twice a week - Allergy to fish - Life threatening pathology (such as cancer) in remission for less than 1 year or still ongoing, - Diabetes (type 1 or type 2), - Cardiovascular disease diagnosed within less that 2 years, with the following exceptions: subjects with controlled (medicated) high blood pressure and/ or controlled (medicated) can be included, - Personal history of stroke - Personal history of schizophrenia or other psychiatric disorders - Ongoing neuroleptic treatment - Current depressive episode characterized at clinical interview according to the criteria of module A of the MINI (Mini International Neuropsychiatric Interview) - Unbalanced thyroid disease (treatment modified in the last 6 months), - For women: hormone replacement therapy started less than 3 months ago or for which the dosage of the treatment has been modified in the last 3 months or whose dosage is likely to be modified during the study - Chronic inflammatory bowel disease or chronic disorders of intestinal absorption - Diagnosed inflammatory bowel disease or chronic intestinal absorption disorders - Current antidepressant treatment or discontinuation within the last 3 months - Substance abuse or alcoholism within the last 6 months (smoking is allowed) - General anesthesia in the last 6 months or scheduled in the next 6 months - Alcohol abuse: more than 2 standard drinks per day, - Subjects with clinical characteristics that may interfere with the performance of the tests (e.g.: acute visual or hearing impairment) - Person placed under court protection, - Person participating in another research study with an exclusion period still in progress ongoing, |
Country | Name | City | State |
---|---|---|---|
France | Laboratoire Nutrition et Neurobiologie Intégrée | Bordeaux | |
France | Plateforme de Recherche Neuro-Psychopharmacologique USR CNRS 3413 SANPSY, CHU de Bordeaux | Bordeaux |
Lead Sponsor | Collaborator |
---|---|
Abyss Ingredients | Laboratoire Nutrition et Neurobiologie intégrée, University Hospital, Bordeaux |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Concentration of fasting blood glucose | baseline and 12 weeks | ||
Other | Concentration of fasting blood Total-cholesterol | baseline and 12 weeks | ||
Other | Concentration of fasting blood HDL-cholesterol | baseline and 12 weeks | ||
Other | Concentration of fasting blood LDL-cholesterol | baseline and 12 weeks | ||
Other | Concentration of fasting blood triglycerides | baseline and 12 weeks | ||
Other | Concentration of cytokines | An inflammatory marker in plasma | baseline and 12 weeks | |
Other | Concentration of oxylipins | An inflammatory marker in plasma | baseline and 12 weeks | |
Other | Concentration of salivary cortisol | Collection 30 minutes after awakening | baseline and 12 weeks | |
Other | Concentration of urinary cortisol | Collection after awakening | baseline and 12 weeks | |
Other | Concentration of urinary cortisol metabolites | Dosage of tetrahydrocortisone and tetrahydrocortisol. Collection after awakening | baseline and 12 weeks | |
Primary | CANTAB - Paired Associate Learning test (PAL TEA = PAL Total Error Adjusted) | 12 weeks | ||
Secondary | CANTAB - Paired Associate Learning test (PAL) | 12 weeks | ||
Secondary | CANTAB - Verbal Recognition Memory (VRM) | 12 weeks | ||
Secondary | CANTAB - Spatial Working Memory test (SWM) | 12 weeks | ||
Secondary | CANTAB - Spatial Span test (SSP) | 12 weeks | ||
Secondary | CANTAB - Reverse Spatial Span test (Reverse SSP) | 12 weeks | ||
Secondary | Perceived Stress Level Scale (PSS) | The Perceived Stress Scale is a 10-item self-administered questionnaire that assesses the frequency with which the respondent has experienced feelings of stress or loss of control over events in the past month. Each item is rated by the patient on a Likert scale from 0 to 4. The total score is obtained by adding the score for each item. The total score is between 0 and 40. A score below 13 suggests a low stress level, a score between 14 and 19 a moderate stress level and a score above 20 a high stress level. | 12 weeks | |
Secondary | Mini-Mental State Examination (MMSE) | The MMSE consists of 30 questions or tasks (items) exploring possible disorders of: orientation in time and space, memory, attention, language (speech, comprehension, reading, writing), motor performance. For each of the thirty questions, a correct answer results in a score of 1 and a wrong or approximate answer in a score of 0. The final score is marked out of 30 points. | 12 weeks | |
Secondary | Geriatric Depression Scale (GDS) | The GDS Short Form is a self-administered questionnaire with 15 items, each with a binary Yes-No response. It was designed to test for depressive symptoms in elderly subjects. In the original form of the scale, an individual with a score of 0 to 5 is considered normal. A score between 5 and 9 indicates a high probability of depression and a score between 10 and 15 almost always indicates depression. | 12 weeks | |
Secondary | Participant's Satisfaction via a multiple choice questionnaire | Each volunteer will filled a multiple choice questionnaire at the end of the study. The galenic choice, organoleptic aspects and the global intake of the product they took will be evaluated. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03896529 -
Neurobiological Mechanisms of Aging and Stress on Prospective Navigation
|
N/A | |
Terminated |
NCT02331771 -
Donepezil Memory Preservation Post ECT
|
N/A | |
Recruiting |
NCT03268109 -
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
|
||
Completed |
NCT00736034 -
The Efficacy of Phosphatidylserine-Omega3 in Elderly Subjects With Memory Impairment
|
Phase 4 | |
Completed |
NCT02814526 -
Exercise in Adults With Mild Memory Problems
|
N/A | |
Recruiting |
NCT05289804 -
Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment
|
Phase 1/Phase 2 | |
Completed |
NCT04955457 -
BDNF Promoter Methylation: Effects on Cognition, Stress and Anxiety and Depression Symptom in Healthy Women.
|
||
Completed |
NCT05033262 -
Our Care Wishes - Dementia
|
N/A | |
Recruiting |
NCT01919957 -
Episodic Memory Before and After Surgery in Drug-resistant Partial Epilepsies
|
N/A | |
Not yet recruiting |
NCT01708200 -
A Comparison of the Effectiveness of Two Types of Memory Training Programs in People With a Diagnosis of Mental Illness.
|
N/A | |
Recruiting |
NCT04583215 -
Enhancing Frontal Lobes Plasticity in Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT05543681 -
IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's
|
Phase 2 | |
Active, not recruiting |
NCT03205709 -
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT02302482 -
Predictive Factors and Autonomy Level Change
|
N/A | |
Completed |
NCT02301247 -
Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)
|
N/A | |
Completed |
NCT01708304 -
Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs)
|
N/A | |
Recruiting |
NCT06025877 -
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
|
||
Recruiting |
NCT05122598 -
Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease
|
Phase 2 | |
Completed |
NCT04473235 -
Better Memory With Literacy Acquisition Later in Life
|
N/A | |
Active, not recruiting |
NCT03661034 -
Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)
|
N/A |